Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis

Reuters
2025.12.08 12:33
portai
I'm PortAI, I can summarize articles.

Cogent Biosciences Inc :COGENT BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE RESULTS OF APEX TRIAL OF BEZUCLASTINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM) COGENT BIOSCIENCES INC - APEX NDA SUBMISSION EXPECTED IN 1H 2026COGENT BIOSCIENCES INC - BEZUCLASTINIB TRIAL SHOWED 89% OF PATIENTS ACHIEVING ≥50% REDUCTION IN BONE MARROW MAST CELLS

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer